Sanofi and other well-known VCs are optimistic about Muna Therapeutics' A round of financing of $73 million

On July 9, 2021, Muna Therapeutics announced the completion of a US$73 million (60 million Euro) Series A financing
.

This round of financing was jointly led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB

Founded in 2020, Muna Therapeutics is headquartered in Copenhagen, Denmark and Leuven, Belgium
.

It is a combination of two innovative European start-up companies .

Muna's innovative whole-person target discovery and verification platform is based on the work of Professor Bart De Strooper and Professor Simon Glerup in the laboratory
.

The two professors have proprietary insights into the molecular pathways that are the basis for disease pathology and neurodegenerative disease recovery in different human brain cell types

"Neurodegenerative diseases such as Alzheimer's disease and frontotemporal dementia affect the cognition and quality of life of patients and caregivers,
" said Ms.

Rita Balice-Gordon, CEO of Muna Therapeutics

Reference materials:

Reference materials:

[1] Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases.

[1] Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases.

Original title: Sanofi and other well-known VCs are optimistic, and Xinrui received US$73 million in Series A financing to promote the research and development of small molecule therapies for neurodegenerative diseases